Edwards Lifesciences Corporation (NYSE:EW) Receives $85.00 Consensus PT from Analysts

Edwards Lifesciences Corporation (NYSE:EW) has received a consensus rating of “Moderate Buy” from the twenty-six research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $85.71.

A number of equities analysts have weighed in on EW shares. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday. Piper Sandler boosted their price objective on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Argus raised Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Robert W. Baird upped their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, July 25th. Finally, Mizuho upped their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daveen Chopra sold 1,500 shares of the company’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the sale, the vice president owned 33,496 shares in the company, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,962 shares of company stock worth $2,641,387. 1.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently bought and sold shares of the stock. Nuveen LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $330,881,000. Jennison Associates LLC increased its holdings in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Edwards Lifesciences by 55.7% in the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company’s stock valued at $430,367,000 after acquiring an additional 2,079,642 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after acquiring an additional 1,678,154 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $92,631,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $81.15 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The business’s 50 day moving average price is $76.73 and its 200-day moving average price is $73.69. The firm has a market capitalization of $47.60 billion, a PE ratio of 11.68, a P/E/G ratio of 3.90 and a beta of 1.11. Edwards Lifesciences has a 1 year low of $59.41 and a 1 year high of $83.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 earnings per share. As a group, equities research analysts expect that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.